

## ERRATUM

# Modeling $\alpha$ -Synuclein Propagation with Preformed Fibril Injections

Hyun Kyung Chung,<sup>1\*</sup> Hoang-Anh Ho,<sup>2\*</sup> Dayana Pérez-Acuña,<sup>1\*</sup> Seung-Jae Lee<sup>1,3</sup>

<sup>1</sup>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

<sup>2</sup>Interdisciplinary Program in Neuroscience, College of Natural Sciences, Seoul National University, Seoul, Korea

<sup>3</sup>Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea

J Mov Disord 2019;12(3):139-151

DOI: <https://doi.org/10.14802/jmd.19046>

In the original version of Table 1 associated with the review article “Modeling  $\alpha$ -Synuclein Propagation with Preformed Fibril Injections”, the “amount of PFF injected” for the Rey et al. 2018 paper should be “0.8  $\mu$ g of 5 mg/ml” instead of “8  $\mu$ g 1 mg/ml”. The injection site mentioned in the “amount of PFFs injected” for Breid et al. 2016 paper should be “intraperitoneal” instead of “intramuscular”. The “amount of PFFs injected” for the Manfredsson et al. 2018 paper should be “6 $\times$ 5  $\mu$ l” instead of “5  $\mu$ g”. Additional information on the concentration of PFFs was added for Breid et al. 2016 paper and Durante et al. 2019 paper, being “1  $\mu$ g/ $\mu$ l” and “1 mg/ml”, respectively.

In the first paragraph of the “SYNUCLEINOPATHIES IN PERIPHERAL PFF INJECTION MODELS” section, we included the description olfactory bulb injection. However, this content belongs to the “SYNUCLEINOPATHIES IN INTRACEREBRAL PFF INJECTION MODELS” section.

**Table 1.** Injection methodologies from recent studies

Author	Year	Injection site	Duration/Time point	Model	Amount of PFFs injected
Luk et al. <sup>20</sup>	2012	Somatosensory cortex and dorsal neostriatum	30 and 90 days post injection (p.i)	M83 mice maintained on a C57BL/6J background, $\alpha$ -syn <sup>-/-</sup> mice maintained on a C57BL/6 background	5 $\mu$ g of 5 mg/mL human $\alpha$ -syn <sup>1-120</sup> Myc or WT full-length human $\alpha$ -syn per brain
Luk et al. <sup>18</sup>	2012	Striatum	30, 90, and 180 days p.i	C57BL/6J F1, C57BL/6/SJL F1, and CD1 mice	5 $\mu$ g of 5 mg/mL full-length WT mouse $\alpha$ -syn per hemisphere
Masuda-Suzukake et al. <sup>40</sup>	2013	Substantia nigra	15 months p.i	4- to 6-month-old female C57BL/6J mice	10 $\mu$ g of mouse or human $\alpha$ -syn PFFs
Guo et al. <sup>60</sup>	2013	Hippocampus	3, 6, and 9 months p.i	2- to 3-month-old PS19 mice or C57BL/6J F1 mice	5 $\mu$ g of PFFs
Sacino et al. <sup>49</sup>	2014	Hippocampus	1, 2, and 4 months p.i	2-month-old M83 mice and M20 mice	2 $\mu$ L of 2 mg/mL hFib 21-140 or $\Delta$ 71-82 $\alpha$ -syn
Sacino et al. <sup>27</sup>	2014	Intramuscular (biceps femoris)	4, 8, and 12 months p.i	2-month-old M83 mice and M20 mice	10 $\mu$ g of mouse PFFs, human 21-140 $\alpha$ -syn PFFs or $\Delta$ 71-82 $\alpha$ -syn
Paumier et al. <sup>48</sup>	2015	Striatum	30, 60, and 180 days p.i	Adult male Sprague-Dawley rats	8 $\mu$ g of mouse or human $\alpha$ -syn PFFs
Osterberg et al. <sup>39</sup>	2015	Cortex	2, 3, and 4 months p.i	2- to 3-month-old $\alpha$ -syn-GFP mice	2.5 $\mu$ L of 2 mg/mL mouse WT $\alpha$ -syn PFFs
Peelaerts et al. <sup>57</sup>	2015	Substantia nigra	4 months p.i	Female Wistar rats	2 $\mu$ L of 5 $\mu$ g/ $\mu$ L $\alpha$ -syn PFFs (total of 10 $\mu$ g)
Breid et al. <sup>30</sup>	2016	Peritoneum, tongue	Up to 420 days p.i	Tg (M83+/-Gfap-luc+/-) and (Gfap-luc+/-) mice	5 $\mu$ L (intraglossal) or 50 $\mu$ L (intraperitoneal) of 1 $\mu$ g/ $\mu$ L sonicated $\alpha$ -syn PFFs
Kim et al. <sup>39</sup>	2016	Striatum	3 and 6 months p.i	3-month-old C57BL/6J mice	5 $\mu$ L of 10 $\mu$ g/ $\mu$ L recombinant $\alpha$ -syn monomer, 2 $\mu$ g/ $\mu$ L LPS(-) fibril seed, and 2 $\mu$ g/ $\mu$ L LPS(+) fibril seed
Thakur et al. <sup>45</sup>	2017	Substantia nigra, ventral tegmental area	10 days p.i	Female Sprague-Dawley rats	2.5 $\mu$ L of full-length recombinant human $\alpha$ -syn PFFs (10 $\mu$ g total) per site
Karampetsou, et al. <sup>21</sup>	2017	Striatum	60 days p.i	2- to 4-month-old male and female wild-type C57BL/6J F1 mice and $\alpha$ -Syn <sup>-/-</sup> mice (C57BL/6J OlaHsd mice)	4.25 $\mu$ g (4 $\mu$ L) of three different types of human recombinant fibrillar $\alpha$ -syn
Abdelmotilib et al. <sup>35</sup>	2017	Striatum	6 months p.i	8- to 10-week-old mice and rats	10 $\mu$ g (mice) or 20 $\mu$ g (rats) of mouse or human $\alpha$ -syn PFFs
Blumenstock et al. <sup>43</sup>	2017	Dorsal striatum	30, 60, and 90 days p.i; 5 and 9 months p.i	2-month-old mice	5 $\mu$ L (25 $\mu$ g) of mouse $\alpha$ -syn PFFs

**Table 1.** Injection methodologies from recent studies (continued)

Author	Year	Injection site	Duration/Time point	Model	Amount of PFFs injected
Sorrentino et al. <sup>56</sup>	2017	IC or CPu	4–5 months p.i	4-month-old M20 non-Tg (NTG) mice	2 $\mu$ L of 2 mg/mL human or mouse WT $\alpha$ -syn PFFs
Harms et al. <sup>63</sup>	2017	Substantia nigra	1, 3, and 6 months p.i	8- to 10-week old Sprague-Dawley rats	8 $\mu$ g of mouse $\alpha$ -syn PFFs
Shimozawa et al. <sup>60</sup>	2017	Caudate and putamen	3 months p.i	26-month-old marmosets	50 $\mu$ L aliquots of 4 mg/mL mouse $\alpha$ -syn PFFs
Okuzumi et al. <sup>44</sup>	2018	Striatum	1 week pi, 0.75, 1.5, 3, and 6 months p.i	2- to 3-month-old C57BL/6J mice	5 $\mu$ g/2.5 $\mu$ L of recombinant mouse or human $\alpha$ -syn PFFs
Rey et al. <sup>29</sup>	2018	Olfactory bulb	1, 2, 3, 6, 9, 12, 18, and 23 months p.i	3-month-old female C57BL/6J mice	0.8 $\mu$ L of 5 mg/ml WT mouse or human $\alpha$ -syn PFFs
Uemura et al. <sup>28</sup>	2018	Mouse gastric wall	45 days p.i	2-month-old male C57BL/6J mice	3 $\mu$ L of 2 $\mu$ g/ $\mu$ L mouse $\alpha$ -syn PFFs
Duffy et al. <sup>47</sup>	2018	Striatum	6 months p.i	2-month-old male Fischer mice	2 $\mu$ L of 2 $\mu$ g/ $\mu$ L mouse $\alpha$ -syn PFFs (unilateral)
Sorrentino et al. <sup>42</sup>	2018	Muscle	1, 2, 3, and 4 months p.i	2-month-old M83+/- mice	2.5, or 10 $\mu$ g of mouse $\alpha$ -syn fibrils
Milanese et al. <sup>41</sup>	2018	Striatum	4 months p.i	C57BL/6 mice	5 $\mu$ g (2.5 $\mu$ L) of human $\alpha$ -syn PFFs
Terada et al. <sup>46</sup>	2018	Striatum	3 months p.i	10-week-old C57BL/6J mice	5 $\mu$ L (150 $\mu$ M) of human WT or truncated $\alpha$ -syn PFFs
Ayers et al. <sup>54</sup>	2018	Sciatic nerve (unilateral)	1, 2, and 4 months p.i and end-stage	M83 and M20 mice	2 $\mu$ L of 2 mg/mL mouse WT or human $\Delta$ 71–82 $\alpha$ -syn PFFs
Manfredsson et al. <sup>55</sup>	2018	Enteric neurons of the descending colon	1, 6, and 12 months p.i	Young adult male Sprague-Dawley rats	6 $\times$ 5 $\mu$ L of 2 $\mu$ g/ $\mu$ L mouse or human $\alpha$ -syn PFFs
Manfredsson et al. <sup>55</sup>	2018	Colon and stomach	12 months p.i	Non-human primates ( <i>Macaca fascicularis</i> )	10 injections of 10 $\mu$ L (2 $\mu$ g/ $\mu$ L)
Peralta Ramos et al. <sup>68</sup>	2019	Vein	12 hours p.i	2-month-old C57BL/6 mice	5 $\mu$ g of Atto 488-labeled $\alpha$ -syn fibrils or ribbons
Durante et al. <sup>77</sup>	2019	Striatum	6, 7 weeks p.i	Male Wistar rats	1 $\mu$ L of 1 mg/ml human $\alpha$ -syn PFFs per site

The table describes the sites of preformed fibril (PFF) injection, the ages of the animals, the amount of seed, and the duration or time points sample analysis used in the experiments. WT: wild type, GFP: green fluorescent protein, LPS: lipopolysaccharide, IC: inferior colliculus, CPu: caudate putamen, NTG: non-Tg.